PEGylated Proteins Market

Global PEGylated Proteins Market Size (2024 to 2029)

The global PEGylated proteins market size was valued at USD 1018.63 million in 2023. The global market size is estimated to be worth USD 1854.3 Million by 2029 from USD 1125.5 Million in 2024, projecting a CAGR of 10.5% from 2024 to 2029.

PEGylation is the process of attaching the strands of the polymer PEG to molecules such as peptides, proteins, and antibody fragments that improve the safety and efficiency of many therapeutics. The PEGylated protein is used to treat anemia, kidney diseases, multiple sclerosis, hemophilia, and cancer. The advancement in the PEGylation process has led to the retention and enhancement of favorable properties of the protein that can be used for therapeutics without losing function. The polymer has high biocompatibility and fewer side effects, increasing the demand for the PEG polymer in the market.

MARKET DRIVERS

The growing adoption of PEGylated proteins and increasing usage of these proteins in various applications are propelling the global PEGylated proteins market growth.

There are significant advancements in the PEGylated protein techniques, which help create more stable and non-immunogenic therapies, which is expected to boost global PEGylated protein market growth. PEGylated proteins are increasingly being used in cancer treatments and the growing cancer patient population is anticipated to boost the market growth. According to the WHO, around 9.6 million people died due to cancer in 2018. The CCN-family protein can be used for the therapy of blood cancer after the PEGylation process. Cancer is one of the major processes that is being targeted using PEGylated drugs thus it is one of the factors boosting the PEGylated proteins market. 

The advantages of PEGylated drugs are further fuelling the market’s growth rate.

The increasing awareness about the benefit of PEGylated protein has increased the acceptance of the product worldwide, which is propelling the market growth. There is a lot of research going on the PEGylated protein to improve the drugs and discover other technique applications. The US FDA approves around 17 PEGylated proteins. Increasing disposable income in urban areas is also leveling up the market's growth rate. The rising cases of chronic diseases in geriatric populations are now promoting the need for the development of drugs.  The multiple benefits associated with PEGylated proteins over the common molecular formula are expected to support its demand during the forecast period. PEGylated proteins help develop the pharmacokinetic abilities of drugs; it helps the slow uptake of drugs to avoid losing the drug efficacy. In addition, the PEGylated drugs help the NPS (inorganic particles) for better absorption of drugs in the target places. It is also known to increase the drug solubility, stability, kidney clearance properties, and overall affinity of the drug. Therefore, the several conveniences and ease of usage of the PEGylated proteins over common drugs are boosting the market’s growth rate.

MARKET RESTRAINTS

The PEGylation of protein is a complex process where it needs trained persons. The lack of experts is a significant factor impeding the growth rate of the global PEGylated proteins market. The prolonged use of PEGylation protein products in treatment can cause lysosomal diseases syndrome, anti–PEG IgM antibodies, bioaccumulation, and hypersensitivity, which is a challenge to market growth.

Impact Of COVID-19 On the Global PEGylated Proteins Market

The COVID-19 disease outbreaks are caused by a novel coronavirus now officially known as extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2). PEGylation modifies biological molecules by conjugating them with a non-immunogenic polymer and a non-toxic polyethylene glycol to enhance their physicochemical properties. COVID-19 is expected to have a minor effect on the PEGylated Proteins Market. The use of polyethylene glycol (PEG) to precipitate SARS-CoV-2 stocks without ultracentrifugation has been introduced, which could help provide a resource for various coronaviruses. Low concentrations of PEG-IFN-alpha-2a, which inhibit MERS-CoV replication in cell culture, can inhibit SARS-CoV-2 replication. As a result of the comprehensive research conducted using PEGylation technology, COVID-19 is expected to impact the industry. PEGylation of therapeutic proteins has improved cancer treatment, leukemia, hepatitis C, rheumatoid arthritis, extreme combined immunodeficiency disease, and Crohn's disease, among other chronic diseases. On the other hand, COVID-19 has caused delays in identifying new cancer cases and the timely delivery of cancer patient treatment. As a result, the market had moderate growth during this pandemic.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global PEGylated Proteins Market Analysis By Protein Type

The interferon segment accounted for the largest share of the global market in 2023 and is expected to register a healthy CAGR during the forecast period owing to massive occurrences of infections associated with chemotherapy, developments made by most of the key market players. In addition, the increasing incidence of viral infections is contributing to the growth rate of the segment.

On the other hand, the monoclonal antibodies segment is expected to showcase a noteworthy CAGR during the forecast period owing to the protein type's high clinical significance and its ability to reduce critical patient death rates through the pathogenesis of the virus. In addition, the fast clearance of virulent patients helps stabilize their conditions and prevents fast deterioration into death.

Global PEGylated Proteins Market Analysis By Consumables

The reagents segment is estimated to occupy a major share of the global PEGylated proteins market during the forecast period. Increasing diseases and also growing disposable income in urban areas are propelling the segmental growth. In addition, PEGylated reagents are used in multiple lab testing and research studies promoting their use. 

However, the PEGylation kits are now on the rise, and their revenue is expected to have a quick CAGR over the forecast period due to the usage of PEGylation kits for research and development purposes. The kits are strong storing agents and help enhance the solubility and stability of the different combinations of sets it provides. The kits also help reduce the immunogenicity of the sets, further promoting their growth. 

Global PEGylated Proteins Market Analysis By Application

The cancer treatment segment is anticipated to endure commanding over the period due to the standard increase of cancer worldwide. Therefore, this segment is considered to showcase the quickest growth during the analysis period. PEGylation as a process has been used for many severe chronic conditions and immunodeficiency diseases due to its ability to improve the pharmacokinetic abilities of the drug. 

However, the chronic kidney diseases segment is expected to be the second fast-growing revenue for the market. The segment's growth can be attributed to the role of PEgylated reagents and kits in drug delivery, research, and treatment of kidney conditions. Consider the PEGylated gold NPs (inorganic particles), for example, which are used in drug absorption for kidney diseases because they help keep the efficacy of the drug intact. 

Global PEGylated Proteins Market Analysis By End-user

The pharmaceuticals and biotechnology companies segment held the largest share of the global PEGylated proteins market in 2023 and the segmental domination is predicted to continue during the forecast period owing to the growing number of investments for the R&D of PEGylated proteins.

However, CROs are now on the rise due to the increased demand for third-party assistance with contract research and the development of drugs. In addition, the industries of biotechnologies and pharmaceuticals are now depending on CROs for assistance because of the hassle-free process and the clearance with the FDA guidelines. 

REGIONAL ANALYSIS

North America is predicted to lead the global market and account for more than 30% of the share in the global market in 2023. Factors such as increasing biologics such as erythropoietin for treating chronic diseases and vital government funds and approvals for research activities drive the North American market. Additionally, an increase in R&D spending on drug discovery at the initial stages is a supporting factor to this regional market growth.

Europe is expected to grow at a promising rate during the forecast period due to increasing awareness about health and pharmacy, economic strength to obtain costly medicines, and approval of reimbursement policies. In Europe, the German market is predicted to lead the EU PEGylated proteins market.

At the same time, Asia-Pacific is expected to grow faster during the forecast period. The growth of the APAC market is majorly driven by the Y-O-Y growth in the prevalence of infectious diseases, growing expenditure on healthcare, and the rising medical tourism industry.

Latin America is projected to grow at a steady CAGR during the forecast period. The Brazilian market is estimated to lead the Latin American market due to increasing awareness of health-related issues.

The Middle East and Africa region is estimated to have a slow growth rate between 2020 to 2025 and is majorly driven by the entry of new key players. Africa is the fastest-growing nation in this region, with the increasing acquisition of protein-based drugs over non-protein-based drugs.

KEY PLAYERS IN THE GLOBAL PEGYLATED PROTEINS MARKET

Some of the major companies dominating the global PEGylated Proteins market profiled in the report are Laysan Bio, Ltd., Iris Biotech GmbH, Biomatrik Inc., Quanta BioDesign Ltd., Cealares GmbH, Creative PEGworks, Jenkem Technology USA Inc., NOF Corporation, Thermo Fisher Scientific Inc., and Merck Millipore.

RECENT HAPPENINGS IN THE GLOBAL PEGYLATED PROTEINS MARKET

• In May 2020, Protalix BioTherapeutics and Chiesi Global Rare Diseases announced the biologics license application submission to US FDA for pegunigalsidase Alfa. It is beneficial for the treatment of Fabry diseases by the product name ProcellEx.
• In April 2020, a French company, Laboratoire Francais du Fractionnement et des biotechnologies (LFB), received clearance from US FDA for Sevenfact (coagulation factor VIIa). 
• In September 2022, Pronalyse is a Contract research organization and a creative proteomics company that has achieved many Millenials in its field of research. The company has now started to step into the biopharmaceuticals field with the introduction of its metabolite identification services. The services are targeted to analyze the metabolism of biological drugs in-vivo. 
• In April 2022, The American association for cancer Research's annual meeting occurred in April at New Orleans, Louisiana this year. The biotechnology company, Bright peak gave one video presentation and two poster presentations at the meeting. The biotechnological enterprise has been known for its research in cancer and autoimmune disorders and for providing immunotherapies for the same.

DETAILED SEGMENTATION OF THE GLOBAL PEGYLATED PROTEINS MARKET INCLUDED IN THIS REPORT

This research report on the global PEGylated proteins market has been segmented based on the protein type, consumables, application, end-user, and region.

By Protein Type

• Interferons 
• Erythropoietin 
• Monoclonal Antibodies (mAbs)

By Consumables

• Reagents 
• PEGylation Kits

By Application

• Chronic Kidney Diseases 
• Cancer Treatment

By End-Users

• Pharmaceuticals & Biotechnology Companies 
• CROs
• Academic Research Institutes

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa